
|Videos|October 29, 2021
Dr. Swerdloff on testosterone capsule for hypogonadal men
Author(s)Urology Times staff
“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.
Advertisement
In this video, Ronald Swerdloff, MD, discusses the takeaways of the study, “Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men,” presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Swerdloff is a professor of medicine and senior investigator at The Lundquist Institute, Harbor-UCLA Medical Center and David Geffen School of Medicine, University of California, Los Angeles.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Treatment Selection in Advanced Prostate Cancer
3
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
4
Advice for the Next Generation of Urologists in mCSPC Management
5






